Framingham Company Developing Alzheimer’s Disease Treatments Launches Initial Public Offering

FRAMINGHAM – Alzheon, Inc. announced today, April 2, it has launched the roadshow for the initial public offering of its common stock.

Alzheon is offering 5 million shares of its common stock at an initial public offering price between $13 and $15 per share.

The Framingham-based company is a “clinical-stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders.”

The company is developing these disease-modifying treatments by leveraging its expertise in inhibiting protein misfolding and aggregation.

Alzheon expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments.

The shares are expected to trade on The Nasdaq Global Market under the ticker symbol “ALZH.”

Citigroup Global Markets Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Canaccord Genuity LLC and JMP Securities LLC are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective.

***

Photo is a screenshot of the Alzheon website

Framingham Source Editor Susan Petroni

Susan Petroni Framingham Source Editor Email: editor@FraminghamSource.com Phone: 508-315-7176

Leave a Reply